You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
British bioinformatics firm PrecisionLife has mined the UK Biobank to identify genetic risk factors for late-stage COVID-19 patients developing sepsis.
Chipscreen is developing a small molecule inhibitor of key serine-threonine kinases involved in tumor angiogenesis, cell mitosis, and microenvironment inflammation.
The assays will combine genomic and gene expression analyses to better understand driver mutations in prostate, breast, and pancreatic cancers.
Experts discussed the benefits and challenges of implementing precision medicine protocols for oncology patients at this week's Tri-Conference meeting
The Dutch multinational is now on track to introduce a kitted version of the assay, which can be run on standard quantitative PCR equipment, by the end of the year.
By pulling in data from Higi health kiosks in retail pharmacies, Interpreta builds continuously updated care from genomics, clinical data, and patient lifestyles.
The British molecular diagnostics company plans to make its array-based test for early-stage Alzheimer's disease available in the US by year end.
The new algorithm, called TOPSPIN, complements the company's MMprofiler test. It is considering making TOPSPIN-generated data available to its MMprofiler patients.
The model incorporates clinical, serological, and gene expression factors, and could be used to tailor treatment choices.
The Cambridge, Massachusetts-based precision medicine firm hopes to translate molecular information into therapies for chronic kidney diseases.
Researchers have developed a robotic lab assistant, the Verge reports.
CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.
The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.
In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.